5 Novel FDA Approvals That Signal a Shift Toward Convenience-Driven Care

Between July 1 and July 24, the FDA approved 5 therapies that point to a broader shift in drug development priorities toward convenience.

An allogeneic regulatory T cell–based immunotherapy with hematopoietic stem and progenitor cell and T cells-vldq became the first approval built on purified regulatory T cells for stem cell transplant¹; atacicept-vymj was the first dual B-cell activating factor (BAFF)/A proliferation-inducing ligand (APRIL) inhibitor approved for IgA nephropathy²; enlicitide is now the first oral PCSK9 inhibitor with regulatory approval to reduce low-density lipoprotein cholesterol (LDL-C)³; zidesamtinib is a novel next-generation option for resistant ROS1-positive (ROS1+) non–small cell lung cancer (NSCLC)⁴; and furosemide injection became the first autoinjector delivering intravenous (IV)-equivalent furosemide at home.⁵

Beyond raw efficacy, each is positioned to displace a more burdensome existing standard, trading infusions, injections, or hospital visits for pills, at-home autoinjectors, or better-tolerated regimens in increasingly competitive treatment landscapes.

1. Orca-T Gains FDA Approval for Matched Donor Stem Cell Transplants (July 1)

The FDA approved allogeneic regulatory T cell–based immunotherapy with hematopoietic stem and progenitor cell and T cells-vldq (Orca-T/Tregzi; Orca Bio), the first therapy built on highly purified regulatory T cells (Tregs), for matched donor stem cell transplants in adults with blood cancers.¹ This personalized cell therapy, supported by data from the phase 3 Precision-T trial (NCT05316701), sequentially delivers stem/progenitor cells, purified Tregs, and conventional T cells to rebuild the immune system while suppressing graft-vs-host disease (GVHD).

In the trial of 187 patients, chronic GVHD-free survival at 12 months was 78% with Orca-T vs 38% with standard transplant, and overall survival rates were 94% and 83%, respectively; chronic GVHD also occurred far less often (12.6% vs 44%). Experts from UCLA, Memorial Sloan Kettering Cancer Center, and Stanford Medicine called it a major advance for preserving antileukemia effects while reducing toxicity. Common adverse effects included mucositis, diarrhea, and infections, although serious infections were less frequent than with conventional transplant.

2. FDA Approves Atacicept for IgA Nephropathy (July 7)

Vera Therapeutics’ atacicept (Trutakna) won accelerated approval as the first dual BAFF/APRIL inhibitor for IgA nephropathy, a progressive kidney disease that pushes at least half of patients toward kidney failure.² In the phase 3 ORIGIN 3 trial (NCT04716231) of 431 adult patients, the at-home weekly injection produced a 46% reduction in proteinuria from baseline and a 42% reduction relative to placebo, the largest placebo-adjusted effect reported to date in a phase 3 IgA nephropathy trial at week 36. Infections and injection-site reactions were the most common adverse effects.

Because this is an accelerated approval, full approval depends on confirmatory kidney-function data expected in Q3 2026 on estimated glomerular filtration rate. The approval adds yet another disease-modifying option to a rapidly competitive IgA nephropathy field, alongside sibeprenlimab and atrasentan, intensifying scrutiny on payer coverage and prior authorization.

3. FDA Approves Enlicitide, First Oral PCSK9 for High Cholesterol (July 16)

Enlicitide (Lipfendra; Merck) became the first oral PCSK9 inhibitor approved for lowering LDL-C, offering a once-daily pill alternative to injectable options like evolocumab and alirocumab.³ Across 2 phase 3 trials, CORALreef Lipids (NCT05952856) and CORALreef HeFH (NCT05952869), enlicitide cut LDL-C by 55.8% and 59.0%, respectively, compared with placebo at 24 weeks, with effects sustained through week 52 and numerically comparable to injectable PCSK9 antibodies.

Adherence was high (97%), and the safety profile was similar to placebo, although diarrhea and dizziness were more common in CORALreef HeFH. Investigators say the oral formulation could expand prescribing beyond specialists, since many primary care physicians have never prescribed an injectable PCSK9 inhibitor. A cardiovascular outcomes trial, CORALreef Outcomes (NCT06008756), will determine whether LDL lowering translates into fewer heart attacks and strokes.

4. FDA OKs Zidesamtinib as New Option for Resistant ROS1+ NSCLC (July 22)

Zidesamtinib (Jideytro; GSK) was approved for adults with ROS1-positive NSCLC who progressed on a prior ROS1 tyrosine kinase inhibitor (TKI).⁴ With this approval, it became GSK’s first approved lung cancer drug gained through its Nuvalent acquisition. The brain-penetrant, ROS1-selective drug is designed to overcome resistance mutations like G2032R while avoiding tropomyosin receptor kinase–related toxicity.

In the ARROS-1 trial (NCT05118789), previously treated patients had a 44% objective response rate (ORR)—but 51% in those with a history of just 1 prior TKI—with 78% of responses lasting through 1 year and 62% lasting through 18 months. The intracranial ORR was 48%, including 20% complete responses, addressing a key unmet need since nearly half of enrolled patients had active brain metastases. The drug was generally well tolerated, with low rates of dose reductions and discontinuations.

5. FDA Approves First Autoinjector for At-Home IV-Equivalent Diuresis (July 24)

MannKind’s furosemide injection (Furoscix ReadyFlow) became the first autoinjector delivering subcutaneous furosemide with IV-equivalent exposure, approved for edema in adults with heart failure or chronic kidney disease.⁵ It delivers an 80-mg/mL dose in under 10 seconds vs approximately 5 hours for the company’s existing on-body infusor, with symptom relief possible within an hour. The investigation that led to its approval (NCT06167707) showed equivalent urine output and electrolyte excretion compared with IV furosemide at 6, 8, and 12 hours, and a safety profile consistent with known furosemide effects.

With heart failure affecting an estimated 6.7 million Americans and driving costly hospitalizations, the device is positioned to help patients manage fluid overload at home, potentially reducing emergency department visits and admissions. The autoinjector is expected to be commercially available by the end of August 2026, with payers expected to weigh its role against oral diuretics and the existing infusor.

References

1. Grossi G. Orca-T gains FDA approval for matched donor stem cell transplants. AJMC^®. July 1, 2026. Accessed August 7, 2026.https://www.ajmc.com/view/orca-t-gains-fda-approval-for-matched-donor-stem-cell-transplant.
2. Hohmann E. FDA approves atacicept for IgA nephropathy. AJMC. July 7, 2026. Accessed August 7, 2026. https://www.ajmc.com/view/fda-approves-atacicept-for-iga-nephropathy
3. Joszt L. FDA approves enlicitide, first oral PCSK9 for high cholesterol. AJMC. July 16, 2026. Accessed August 7, 2026. https://www.ajmc.com/view/fda-approves-enlicitide-first-oral-pcsk9-for-high-cholesterol
4. McCormick B. FDA OKs zidesamtinib as new option for resistant ROS1+ NSCLC. AJMC. July 22, 2026. Accessed August 7, 2026. https://www.ajmc.com/view/fda-approves-zidesamtinib-offering-new-option-for-resistant-ros1-positive-nsclc
5. Steinzor P. FDA approves first autoinjector for at-home IV-equivalent diuresis. AJMC. July 24, 2026. Accessed August 7, 2026. https://www.ajmc.com/view/fda-approves-first-autoinjector-for-at-home-iv-equivalent-diuresis